Theoretical analysis of the cannabinoid action in breast cancer metabolic pathways by systems biology and sistematic literature review
DOI:
https://doi.org/10.54372/sb.2021.v16.3019Keywords:
canabinoides, câncer de mama, canabidiol, gpcr, STAT3.Abstract
Breast cancer is the most common and incident kind of tumor. Despite the significative advances on treatment, there are gaps regarding the understanding of the therapy resistance mechanisms. The cannabinoids have shown considerable activity in breast tumors treatment of both in vitro and in vivo. Given the heterogenic profile of this kind of tumor, and the complexity of the therapeutical potential of the cannabinoids, it is necessary to identify the acting metabolic pathways of these compounds for the development of medicines to treat diseases like breast cancer. In this paper, through a systematic literature review and data obtained at the StringDB database, it was aimed to explain the role of the cannabidiol cannabinoid on MDA-MB-231 breast cancer cells. It was found that the classic JAK-STAT pathway can be crucial for cannabidiol acting on breast cancer, knowing that the STAT3 protein can be activated through G-protein coupled receptors, which are a negative allosteric modulation target from cannabidiol. It was concluded that the cannabidiol’s effect on its respective receptor can promote their modulation and, as consequence, the non-activation of STAT3.
References
(1) BONINI, Sara Anna et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of Ethnopharmacology, [s.l.], v. 227, p. 300-315, set. 2018.
(2) VELASCO, Guillermo; SÁNCHEZ Cristina; GUZMÁN, Manuel. Cancer. In: PERTWEE, Roger G. (Ed). Handbook of Cannabis. 1. ed. Nova Iorque: Oxford University Press, 2014. Cap. 35, p. 626-643.
(3) FRAGUAS-SÁNCHEZ, Ana Isabel; TORRES-SÁNCHEZ, Ana Isabel. Medical use of Cannabinoids. Drugs. [s.l.], v. 78, n. 16, p. 1665-1703, nov. 2018.
(4) INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. ABC do câncer: abordagens básicas para o controle do câncer. 3 ed. rev. atual. Rio de Janeiro. 2017. 108 p.
(5) FORMAN, David; FERLAY, Jacques. The global and regional burden of cancer. In: STEWART, Bernard W. (Ed.); WILD, Christopher P. World Cancer Report 2014. 1. ed. Lyon: International Agency for Research on Cancer, 2014. cap.1, p. 16-53.
(6) CALDEIRA, Izabela Daniel Sardinha. Papel da nova citocina FAM3B/PANDER na progressão tumoral em câncer de mama. Dissertação (Mestrado)-Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, 2016.
(7) ROCHA, José Cláudio Casali de; RAMIREZ Ricardo; COSTA, Susanne Cocramo Ventilari da. Câncer de Mama. In: FERREIRA, Carlos Gil (Ed.); ROCHA, José Cláudio Casali da. (Ed.). Oncologia Molecular. 2. ed. São Paulo: Atheneu, 2010. Cap. 16, p. 217-225.
(8) GARDY, Jennifer L. et al. Enabling a systems biology approach to immunology: focus on innate immunity. Trends In Immunology, [s.l.], v. 30, n. 6, p. 249-262, jun. 2009.
(9) BARABÁSI, Albert-lászló; GULBAHCE, Natali; LOSCALZO, Joseph. Network medicine: a network-based approach to human disease. Nature Reviews Genetics, [s.l.], v. 12, n. 1, p. 56-68, 17 dez. 2010.
(10) KOSGODAGE, Uchini S. et al. Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. Frontiers in Phamacology. [s.l.], v. 9, p. 889, 13 ago. 2018.
(11) PULLAN, Jessica E. et. al. Exosomes as Drug Carriers for Cancer Therapy. Mol. Pharmaceutics. [s.l.], v. 16, p. 1789-1798, 5 abr. 2019.
(12) VALADI, Hadi et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, [s.l.], v. 9, n. 6, p. 654-659, 7 maio 2007.
(13) RASHED, Mohammed H. et. al. Exossomes: From Garbage Bins to Promising Therapeutic Targets. International Journal of Molecular Sciences. [s.l.], v. 18, p. 538, 2 mar. 2017.
(14) SUBRAMANIAM, Aruljothi et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochimica Et Biophysica Acta (bba) - Reviews On Cancer, [s.l.], v. 1835, n. 1, p. 46-60, jan. 2013.
(15) AVALLE, Lidia et al. STAT3 in cancer: A double edged sword. Cytokine, [s.l.], v. 98, p. 42-50, out. 2017.
(16) JUNIOR, Tharcísio C T. Proibitina e a resposta a mecanismos de estresse em melanoma e sua relação com a via E2F1. Tese (Doutorado)-Faculdade de Medicina, Universidade de São Paulo, São Paulo, 2013.
(17) BRASIL: Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Diretrizes metodológicas: elaboração de revisão sistemática e metanálise de ensaios clínicos randomizados. Brasília, DF, 2012. 92 p.
(18) SZKLARCZYK, Damian et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Research, [s.l.] v. 45, p. 362-368, out. 2016.
(19) ELBAZ, Mohamad et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. Molecular Oncology, [s.l.] v. 9, n. 49, p. 906-61, jan. 2015.
(20) MURASE, Ryuichi et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Frontiers in Phamacology. [s.l.], v. 171, p. 4464-4477, jun 2014.
(21) TAKEDA, Shuso et al. Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness. Journal Of Natural Medicines, [s.l.], v. 71, n. 1, p. 286-291, 16 ago. 2016.
(22) TAKEDA, Shuso et al. Δ9-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPARα in MDA-MB-231 breast cancer cells. Toxicology, [s.l.], v. 326, p. 18-24, dez. 2014.
(23) SULTAN, Ahmed S.; MARIE, Mona A.; SHEWEITA, Salah A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. The Breast, [s.l.], v. 41, p. 34-41, out. 2018.
(24) BLASCO-BENITO, Sandra et al. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical Pharmacology, [s.l.], v. 157, p. 285-293, nov. 2018.
(25) TAKEDA, Shuso et al. Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. The Journal of Toxicological Sciences, [s.l.], v. 39, n. 5, p. 711-716, 2014.
(26) EMERY, S. M. et al. Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells. Journal Of Pharmacology And Experimental Therapeutics, [s.l.], v. 348, n. 2, p. 293-302, 20 nov. 2013.
(27) XIAN, Susan et al. The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer. Anticancer research, [s.l.], v. 35, n. 9, p. 4707-4712, set. 2015.
(28) ANDERAH, Todd et al. Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer: Targets and Therapy, [s.l.], p. 59-59, abr. 2016.
(29) DARNELL, J.E.; Jr., KERR, I.M.; STARK, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, [s.l.], v. 264, p. 1415–1421, 3 jun. 1994.
(30) FREITAS, Maria C. S. Avaliação do papel da proteína tirosina-kinase janus kinase 2 (JAK2) em modelo murinho de lesão hepática induzida por isquemia e reperfusão. Tese (Doutorado)-Escola Paulista de Medicina, Universidade de São Paulo, São Paulo, 2010.
(31) MURRAY, P. J. The JAK-STAT Signaling Pathway: Input and Output Integration. The Journal Of Immunology, [s.l.], v. 178, n. 5, p. 2623-2629, 20 fev. 2007.
(32) KIM, Ji et al. Inhibition of tumor growth and angiogenesis of tamoxifen resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. Oncology Letters, [s.l.], p. 3981-3989, 20 fev. 2019.
(33) YUAN, Jie; ZHANG, Fei; NIU, Ruifang. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Scientific Reports, [s.l.], v. 5, n. 1, p. 17663, 3 dez. 2015.
(34) YU, Hua et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nature Reviews Cancer, [s.l.], v. 14, n. 11, p.736-746, 24 out. 2014.
(35) LAPPANO, Rosamaria; JACQUOT, Yves; MAGGIOLINI, Marcello. GPCR Modulation in Breast Cancer. International Journal Of Molecular Sciences, [s.l.], v. 19, n. 12, p. 3840-3840, 2 dez. 2018.
(36) LEE, Heehyoung et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nature Medicine, [s.l.], v. 16, n. 12, p. 1421-1428, 21 nov. 2010.
(37) XIN, Hong et al. G-protein-coupled Receptor Agonist BV8/Prokineticin-2 and STAT3 Protein Form a Feed-forward Loop in Both Normal and Malignant Myeloid Cells. Journal Of Biological Chemistry, [s.l.], v. 288, n. 19, p. 13842-13849, 2 abr. 2013.
(38) KISKOVÁ, Terézia et al. Future Aspects for Cannabinoids in Breast Cancer Therapy. International Journal Of Molecular Sciences, [s.l.], v. 20, n. 7, p. 1673, 3 abr. 2019.
(39) LAPRAIRIE, R B et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal Of Pharmacology, [s.l.], v. 172, n. 20, p. 4790-4805, out. 2015.
(40) MARTÍNEZ-PINILLA, Eva et al. Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. Frontiers In Pharmacology, [s.l.], v. 8, p. 744, 23 out. 2017.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 SaBios-Revista de Saúde e Biologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Direitos Autorais para artigos publicados nesta revista são cedidos pelo autor à SaBios-Revista de Saúde e Biologia, que está autorizada a publicá-lo em meio impresso, digital, ou outro existente, sem retribuição financeira para os autores. Em virtude da aparecerem nesta revista de acesso público, os artigos são de uso gratuito, com atribuições próprias, em aplicações educacionais e não-comerciais.
Copyright of articles published in this journal are transferred by the author to SaBios-Journal of Health and Biology, which is authorized to publish them in printed, digital or other existing way, without financial reward for authors. Considering that articles appear in this public accessed journal, they are free to be used in educational and non-commercial applications.
